Hostname: page-component-77c89778f8-rkxrd Total loading time: 0 Render date: 2024-07-16T21:54:26.110Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost Effectiveness and Cost Benefit of Vaccination Against Pneumococcal Pneumonia. Implications for Clinical Practice

Published online by Cambridge University Press:  02 January 2015

Jane Sisk Willems
Jane Sisk Willems*
Affiliation:
Health Program, Office of Technology Assessment, U.S. Congress, Washington, D.C
*
Health Program, Office of Technology Assessment, U.S. Congress, Washington, D.C. 20510
Get access Rights & Permissions [Opens in a new window]

Abstract

The economic techniques of cost-effectiveness and cost-benefit analysis have provided useful insights into the potential advantages of vaccination against pneumococcal pneumonia. They suggest that the cost of vaccinating persons 65 years and older and perhaps younger persons with high risk conditions would be reasonable when compared with the cost of treatment for pneumococcal pneumonia. These findings, together with other considerations, may guide physicians and health care policymakers in deciding which individuals might be expected to benefit from pneumococcal vaccination.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 3 , Issue 4 , August 1982 , pp. 299 - 302
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1982

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Office of Technology Assessment. US Congress. A review of selected federal vaccine and immunization policies. Washington, DC, US Government Printing Office, 1979.Google Scholar
2. Willems, JS, Sanders, CR, Riddiough, MA, et al: Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 303:553–559, 1980.CrossRefGoogle ScholarPubMed
3. Recommendation of the Public Health Service Advisory Committee on Immunization Practices. Pneumococcal polysaccharide vaccine. Morb Mort Weekly Rep 27:25–31, 1978.Google Scholar
4. Patrick, KM, Woolley, FR: Cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 245:473–477, 1981.Google Scholar
5. Rytel, MW: Pneumococcal infectionsandpneumococcal vaccine: An update. Infect Control 3(4):295–298, 1982.CrossRefGoogle ScholarPubMed
6. Fraser, DW, Broome, CV: Pneumococcal vaccine: To use or not (editorial). JAMA 245:498–499, 1981.Google Scholar
7. Broome, CV, Facklam, RR, Fraser, DW: Pneumococcal disease after pneumococcal vaccination: An alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 303:549–552, 1980.Google Scholar
8. Pantell, RH, Stewart, TJ: The pneumococcal vaccine: Immunization at a crossroad. JAMA 241:2272–2274, 1979.Google Scholar
9. Barclay, WR: Vaccination to prevent pneumonia (editorial). JAMA 241:2299, 1979.Google Scholar